GRANULES Stock Overview
Granules India Limited fabrica y vende principios activos farmacéuticos (API), productos intermedios de formulación farmacéutica y dosis acabadas (FD) en India, Norteamérica, Europa, Latinoamérica, África, Oriente Medio e internacionalmente.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Granules India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹425.25 |
| 52 Week High | ₹480.45 |
| 52 Week Low | ₹272.35 |
| Beta | 0.29 |
| 1 Month Change | -7.15% |
| 3 Month Change | 5.25% |
| 1 Year Change | 44.79% |
| 3 Year Change | 33.68% |
| 5 Year Change | 273.19% |
| Change since IPO | 3,983.05% |
Recent News & Updates
Investors Holding Back On Granules India Limited (NSE:GRANULES)
Apr 08
Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next
Jan 26Recent updates
Investors Holding Back On Granules India Limited (NSE:GRANULES)
Apr 08Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next
Jan 26Many Still Looking Away From Granules India Limited (NSE:GRANULES)
Dec 28Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet
Nov 13A Look At The Fair Value Of Granules India Limited (NSE:GRANULES)
Oct 24Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?
May 19Should You Be Adding Granules India (NSE:GRANULES) To Your Watchlist Today?
Mar 29Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet
Jan 19Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?
Oct 01Estimating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)
Aug 18Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.75
Jul 14Is Granules India (NSE:GRANULES) A Risky Investment?
Jun 28Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.75
Jun 09Estimating The Fair Value Of Granules India Limited (NSE:GRANULES)
May 06Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.25
Feb 10Calculating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)
Feb 02Here's Why We Think Granules India (NSE:GRANULES) Is Well Worth Watching
Jan 20These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well
Dec 21Here's Why I Think Granules India (NSE:GRANULES) Is An Interesting Stock
Aug 18Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.25
Aug 03Is Granules India (NSE:GRANULES) Using Too Much Debt?
Jun 11Why Granules India Limited (NSE:GRANULES) Is A Dividend Rockstar
May 02Does This Valuation Of Granules India Limited (NSE:GRANULES) Imply Investors Are Overpaying?
Mar 26What Kind Of Investors Own Most Of Granules India Limited (NSE:GRANULES)?
Mar 14These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well
Mar 01Granules India Limited (NSE:GRANULES) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Feb 16Why You Might Be Interested In Granules India Limited (NSE:GRANULES) For Its Upcoming Dividend
Feb 03Analysts Have Made A Financial Statement On Granules India Limited's (NSE:GRANULES) Third-Quarter Report
Jan 30Here's Why We Think Granules India (NSE:GRANULES) Is Well Worth Watching
Jan 20
Have Insiders Sold Granules India Limited (NSE:GRANULES) Shares Recently?
Jan 07Announcing: Granules India (NSE:GRANULES) Stock Increased An Energizing 198% In The Last Year
Dec 28Granules India Limited's (NSE:GRANULES) Attractive Combination: Does It Earn A Place In Your Dividend Portfolio?
Dec 15Could The Granules India Limited (NSE:GRANULES) Ownership Structure Tell Us Something Useful?
Dec 02Shareholder Returns
| GRANULES | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -4.6% | 0.006% | 1.9% |
| 1Y | 44.8% | 62.1% | 49.0% |
Rentabilidad frente al sector: GRANULES obtuvo unos resultados inferiores a los del sector Indian Pharmaceuticals , que el año pasado arrojó un rendimiento del 69.3%.
Rentabilidad vs. Mercado: GRANULES obtuvo unos resultados inferiores a los del mercado Indian, que fue del 49% el año pasado.
Price Volatility
| GRANULES volatility | |
|---|---|
| GRANULES Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: GRANULES no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de GRANULES (4%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 3,650 | Krishna Chigurupati | https://www.granulesindia.com |
Granules India Limited fabrica y vende principios activos farmacéuticos (API), productos intermedios de formulación farmacéutica y dosis acabadas (FD) en India, Norteamérica, Europa, Latinoamérica, África, Oriente Medio e internacionalmente. Entre los principios activos de la empresa en diversas categorías terapéuticas figuran antirretrovirales, antihipertensivos, antihistamínicos, antiinfecciosos, analgésicos, anticoagulantes, antifibriósicos e inhibidores plaquetarios. También ofrece diversos FD, como comprimidos, caplets y cápsulas a presión a granel, en blíster y frascos; y otros productos para oncología.
Granules India Limited Fundamentals Summary
| GRANULES fundamental statistics | |
|---|---|
| Market cap | ₹103.07b |
| Earnings (TTM) | ₹3.95b |
| Revenue (TTM) | ₹45.26b |
26.1x
P/E Ratio2.3x
P/S RatioIs GRANULES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRANULES income statement (TTM) | |
|---|---|
| Revenue | ₹45.26b |
| Cost of Revenue | ₹22.60b |
| Gross Profit | ₹22.66b |
| Other Expenses | ₹18.71b |
| Earnings | ₹3.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.31 |
| Gross Margin | 50.06% |
| Net Profit Margin | 8.73% |
| Debt/Equity Ratio | 46.5% |
How did GRANULES perform over the long term?
See historical performance and comparison